Skip to main content

Crohn's, Colitis Care Take Big Financial Toll on Patients

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 10, 2024.

By Dennis Thompson HealthDay Reporter

THURSDAY, Oct. 10, 2024 -- Inflammatory bowel conditions such as Crohn’s disease and colitis cause intense financial pressure as well as physical distress, a new study shows.

More than 40% of people with inflammatory bowel disease have made significant financial trade-offs to afford the health care they need, according to a new survey by the Crohn’s & Colitis Foundation of America.

That includes giving up vacations or major household purchases (30%), increasing credit card debt (22%), and cutting back on essential items like food or clothing (21%).

"These findings underscore the urgent need to address healthcare disparities in IBD care," Michael Osso, president & CEO of the Crohn's & Colitis Foundation, said in a news release.

"Despite our progress in IBD research and treatment options, many patients still struggle to access the care they need without facing undue burden,” Osso continued. “Our survey findings highlight the critical need for reforms to ensure that IBD patients can access the medications they need without undue financial hardship."

Among those taking meds for their condition, 63% don’t take their IBD drugs as prescribed due to financial barriers. As a result, 66% experienced adverse health events.

The survey also found that 56% faced medication access issues due to insurance problems. For example, 25% had to try and fail on other medications before getting their prescribed treatment.

IBD medications like biologics can be pricey, but are necessary for effective management of the chronic disease, researchers noted. Annual costs of drugs and hospital stays can reach tens of thousands of dollars.

The survey included responses from more than 2,200 IBD patients and caregivers.

The results were published Oct. 8 in the journal Inflammatory Bowel Diseases.

Sources

  • Crohn's & Colitis Foundation, news release, Oct. 8, 2024

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted October 2024

Read this next

FDA Approves Tremfya for Active Crohn Disease in Adults

MONDAY, March 24, 2025 -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active Crohn disease. This...

Can't Find a Gastroenterologist? You're Not Alone

MONDAY, Feb. 17, 2025 -- Nearly 50 million Americans live in counties with no local gastroenterologist. Gastroenterologists diagnose and treat disorders affecting the GI tract --...

FDA Approves Omvoh for Moderately to Severely Active Crohn Disease

THURSDAY, Jan. 16, 2025 -- The U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.